Across TCGA pan-cancer cohorts, ARL2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARL2 data layer compared with 26 for mass-spec protein and 3 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ARL2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ARL2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.
PDAC, CCRCC, and HNSC are the cancer types where ARL2 mass-spec protein most reproducibly stratifies survival.
mass-spec protein survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.